Search: WFRF:(Kunovac Kallak Theodora) >
Sexual dysfunction ...
Sexual dysfunction in women on adjuvant endocrine therapy after breast cancer
-
- Baumgart, Juliane, 1978- (author)
- Örebro universitet,Institutionen för hälsovetenskap och medicin,Region Örebro län,Department of Obstetrics and Gynecology, Örebro University Hospital, Örebro
-
- Nilsson, Kerstin, 1953- (author)
- Örebro universitet,Institutionen för hälsovetenskap och medicin,Region Örebro län,Department of Obstetrics and Gynecology, Örebro University Hospital, Örebro
-
- Stavreus-Evers, Anneli, 1955- (author)
- Uppsala universitet,Obstetrik & gynekologi,Klinisk och experimentell reproduktionsbiologi/Olovsson
-
show more...
-
- Kallak, Theodora Kunovac, 1985- (author)
- Uppsala universitet,Obstetrik & gynekologi,Klinisk och experimentell reproduktionsbiologi/Olovsson
-
- Sundström Poromaa, Inger (author)
- Uppsala universitet,Obstetrik & gynekologi,Reproduktiv hälsa/Sundström Poromaa
-
show less...
-
(creator_code:org_t)
- Lippincott Williams & Wilkins, 2013
- 2013
- English.
-
In: Menopause. - : Lippincott Williams & Wilkins. - 1072-3714 .- 1530-0374. ; 20:2, s. 162-168
- Related links:
-
https://urn.kb.se/re...
-
show more...
-
https://doi.org/10.1...
-
https://urn.kb.se/re...
-
show less...
Abstract
Subject headings
Close
- Objective: The goal of this study was to investigate sexual function in postmenopausal breast cancer patients treated with aromatase inhibitors.Methods: A population-based, cross-sectional study was conducted among postmenopausal breast cancer patients on adjuvant endocrine treatment and age-matched controls with and without estrogen treatment. Sexual function was assessed with a standardized questionnaire.Results: In all, 42.4% of aromatase inhibitor-treated breast cancer patients were dissatisfied with their sex life in general, and 50.0% reported low sexual interest; this was significantly more common than in tamoxifen-treated patients and controls (P < 0.05). Aromatase inhibitorYtreated patients reported insufficient lubrication in 73.9% and dyspareunia in 56.5% of cases, which were significantly more common than in controls, irrespective of hormonal use (P < 0.05). Tamoxifen-treated patients reported significantly more dyspareunia (31.3%; P < 0.05) but resembled controls in all other concerns.Conclusions: Our findings suggest that sexual dysfunction in aromatase inhibitorYtreated women is a greatly underestimated problem.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Allmänmedicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- General Practice (hsv//eng)
Keyword
- Aromatase inhibitors
- Breast cancer
- Postmenopausal women
- Sexual dysfunction
- Tamoxifen
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
-
Menopause
(Search for host publication in LIBRIS)
To the university's database